Clinical Trials Logo

Lung Cancer Metastatic clinical trials

View clinical trials related to Lung Cancer Metastatic.

Filter by:

NCT ID: NCT03272971 Terminated - Lung Cancer Clinical Trials

Feasibility Study of the RF Ablation Catheter to Ablate Lung Tumors

Start date: December 5, 2017
Phase: N/A
Study type: Interventional

The feasibility of a RF ablation catheter to bronchoscopically ablate lung tumors, will be evaluated in patients already scheduled for surgical resection.

NCT ID: NCT03184571 Completed - NSCLC Stage IV Clinical Trials

Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC

Start date: October 17, 2017
Phase: Phase 2
Study type: Interventional

This is an open-label, multi-center, single arm, phase II study to assess the anti-tumor activity and safety of bemcentinib when given in combination with pembrolizumab in up to 106 participants with previously treated, advanced adenocarcinoma of the lung. The study will enroll three cohorts of participants with previously treated, advanced adenocarcinoma of the lung: Cohort A will consist of participants who received a maximum of 1 prior line of platinum-containing chemotherapy and no prior immunotherapy of any kind. Cohort B will consist of participants who received a maximum of one prior line of an anti-programmed death receptor (PD)-(L)1 therapy (monotherapy). Cohort C will consist of participants who received a maximum of one prior line of therapy with an anti-PD-(L)1 therapy in combination with a platinum-containing chemotherapy.The primary objective is to assess the anti-tumor activity of bemcentinib and pembrolizumab when given in combination.

NCT ID: NCT03179150 Completed - Clinical trials for Lung Cancer Metastatic

Clinical Validation of the M5L Lung CAD

Start date: September 1, 2015
Phase: N/A
Study type: Observational

To compare the diagnostic performance and time efficiency of Computer-Aided Detection (CAD) assisted reading for the identification of pulmonary nodules in chest Computed Tomography (CT) from oncological patients with that of unassisted reading.

NCT ID: NCT03113851 Completed - Clinical trials for Lung Cancer Metastatic

Abscopal Effect of Radiation in Combination With rhGM-CSF for Metastatic Non-small Cell Lung Cancer

Start date: August 14, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether radiation combined with recombined human granulocyte-macrophage colony stimulating factor(rhGM-CSF) is safe and effective for patients with metastatic non-small cell lung cancer.

NCT ID: NCT03076164 Completed - Lung Cancer Clinical Trials

A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib

Start date: March 1, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the safety, tolerability and overall response rate of trametinib when given in combination with erlotinib in patients with Stage IV or recurrent lung adenocarcinoma that cannot be treated with curative intent.

NCT ID: NCT03057106 Active, not recruiting - Clinical trials for Lung Cancer Metastatic

Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC

Start date: March 28, 2017
Phase: Phase 2
Study type: Interventional

Durvalumab is a new type of drug for many kinds of cancer. It is considered "immunotherapy" and not "chemotherapy". Laboratory tests show that it works by allowing the immune system to detect cancer and reactivate the immune response. This may help to slow down the growth of cancer or may cause cancer cells to die. Durvalumab has been shown to shrink tumours in animals and has been studied in more than 5000 people and seems promising. Tremelimumab is a new type of drug for various types of cancers. It works in a similar way to durvalumab and may improve the effect of durvalumab. Tremelimumab may also help slow the growth of the cancer cells or may cause cancer cells to die. It has been shown to shrink tumours in animals and has been studied in over 1200 people and seems promising.

NCT ID: NCT02976740 Recruiting - Clinical trials for Lung Cancer Metastatic

SBRT Combination With rhGM-CSF and Tα1 for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy

Start date: November 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether stereotactic body radiotherapy (SBRT) combined with recombined human granulocyte-macrophage colony stimulating factor(rhGM-CSF) and Thymosin Alpha 1 is safe, effective in the treatment of stage IV NSCLC patients who failed in second-line chemotherapy.

NCT ID: NCT02308865 Terminated - Clinical trials for Lung Cancer Metastatic

Early Palliative Care in Metastatic Lung Cancer in Northern France

IMPAQ
Start date: October 17, 2014
Phase: N/A
Study type: Interventional

Single-center, prospective, controlled, open-label, randomized, two parallel arms comparing early Palliative care versus Standard care in patients with non-small-cell metastatic lung cancer